Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein antibody and antigen (recombinant protein)
Diagnostic anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein antibodies pairs and antigen for animal health (animal Fish infectious disease Viral hemorrhagic septicemia) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Fish disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-VT-P231-Tg001-Ag01 | Recombinant Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein protein | $3090.00 |
GMP-VT-P231-Tg001-Ab01 | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P231-Tg001-Ab02 | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein mouse monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P231-Tg001-Ab03 | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein human monoclonal antibody (mAb) | $3090.00 |
GMP-VT-P231-Tg001-Ab04 | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-VT-P231-Tg001-Ag01 |
Product Name | Recombinant Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein protein |
Pathogen | Viral Haemorrhagic Septicaemia Virus |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Viral Haemorrhagic Septicaemia Virus level test of animal Fish infectious disease with Viral hemorrhagic septicemia. |
Tag | His | Product description | Recombinant Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P231-Tg001-Ab01,GMP-VT-P231-Tg001-Ab02 |
Pathogen | Viral Haemorrhagic Septicaemia Virus |
Product Name | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Viral Haemorrhagic Septicaemia Virus antibodies in Viral Haemorrhagic Septicaemia Virus level test of animal Fish infectious disease with Viral hemorrhagic septicemia. |
Product description | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Viral Haemorrhagic Septicaemia Virus antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-VT-P231-Tg001-Ab03,GMP-VT-P231-Tg001-Ab04 |
Pathogen | Viral Haemorrhagic Septicaemia Virus |
Product Name | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Viral Haemorrhagic Septicaemia Virus antibodies in Viral Haemorrhagic Septicaemia Virus level test of animal Fish infectious disease with Viral hemorrhagic septicemia. |
Product description | Anti-Viral Haemorrhagic Septicaemia Virus nucleocapsid (N) protein mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Figure 2. SDS-PAGE under reduced conditions and SEC-HPLC test result of GMP-VT-P231-Tg001-Ab02
Figure 2. SDS-PAGE under reduced conditions and SEC-HPLC test result of GMP-VT-P231-Tg001-Ab03
Click to get more Data / Case study about the product.
Pathogen Information
Aujeszky's Disease Virus (ADV), also known as Pseudorabies Virus (PRV), is a highly contagious and economically significant pathogen that primarily infects pigs. It belongs to the Herpesviridae family, which is a diverse group of enveloped, double-stranded DNA viruses that are capable of infecting a broad range of hosts, including humans.
ADV has a complex structure that comprises multiple components, including glycoprotein B (gB), glycoprotein C (gC), glycoprotein D (gD), and glycoprotein E (gE). These proteins are encoded by the viral genome and play key roles in viral entry, replication, and immune evasion.
The gB protein is essential for viral fusion with cell membranes, while the gC protein promotes viral attachment to host cells. The gD protein mediates virus entry into host cells by binding to specific cellular receptors, while the gE protein is important for virus assembly and release from infected cells. ADV also produces several non-structural proteins that interact with host factors, leading to viral replication and pathogenesis.
In pigs, ADV infection causes Aujeszky's disease, which is characterized by a range of clinical signs such as anorexia, fever, respiratory distress, and nervous system disorders. The virus can establish lifelong persistence and shedding in the tonsils and nasal cavities of infected animals, leading to prolonged transmission and enhanced disease spread.
ADV is a zoonotic pathogen, meaning it can infect humans who come into contact with infected animals or contaminated materials. Although human infections are rare, they can occur through direct or indirect contact with infected pigs or their secretions.
To prevent and control ADV infections, various methods have been developed for its detection and diagnosis. These methods include nucleic acid-based techniques such as polymerase chain reaction (PCR) and real-time PCR, which target genes such as gB or gD and can detect viral DNA in clinical samples with high sensitivity and specificity. Additionally, virus isolation in cell culture and serological assays like enzyme-linked immunosorbent assay (ELISA) detecting anti-ADV antibodies in the blood can be used for diagnosis.
Control measures for ADV include vaccination and biosecurity measures to prevent or limit disease transmission. Several ADV vaccines are currently available, including live attenuated and killed virus vaccines, which provide effective protection against the disease. In addition, strict biosecurity practices such as quarantine, disinfection, and limiting animal movements can help prevent or reduce the spread of the virus.
In conclusion, Aujeszky's Disease Virus is a highly infectious and economically significant pathogen that primarily infects pigs but also has zoonotic potential. Its complex structure and interaction with the host immune system contribute to its virulence and persistence. Detection and control measures such as nucleic acid-based techniques and vaccination can help mitigate the impact of this pathogen.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.